AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
